SCHEDULE: ILJIN Entities Reduce Aurinia Stake Below 5%

ILJIN SNT, ILJIN Steel, and ILJIN GLS, along with individuals Sae Kyoung Huh, Seoung Eun Huh, and Chin Kyu Huh, have filed an amendment to their Schedule 13D, reporting a decrease in their beneficial ownership of Aurinia Pharmaceuticals Inc. common shares to below 5%.

Summary

• This filing is an amendment (Amendment No. 17) to a previously filed Schedule 13D concerning Aurinia Pharmaceuticals Inc. common shares.
• The reporting persons, including ILJIN SNT Co., Ltd., ILJIN Steel Co., Ltd., ILJIN GLS Co., Ltd., Sae Kyoung Huh, Seoung Eun Huh, and Chin Kyu Huh, are reducing their aggregate beneficial ownership of Aurinia Pharmaceuticals Inc. common shares.
• As of August 20, 2026, their combined ownership has fallen below the 5% threshold, meaning they will no longer be required to file reports under Section 13(d) of the Act.
• This reduction is a result of sales of common shares that occurred between June 30, 2026, and August 20, 2026.
• The total number of outstanding common shares of Aurinia Pharmaceuticals Inc. was reported as 133,051,168 as of August 5, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, as the reporting persons are reducing their stake below the threshold requiring disclosure, indicating a potential exit or reduced conviction.

Negatives

• The reporting persons are reducing their stake in Aurinia Pharmaceuticals Inc. to below 5% of outstanding shares.
• Significant sales of common shares occurred in July and August 2026, leading to this reduction in ownership.
• ILJIN SNT sold a total of 423,904 shares between July 16 and August 7, 2026.
• ILJIN Steel sold 200,000 shares on August 20, 2026.
• Seoung Eun Huh sold a total of 16,391 shares between June 30 and August 6, 2026.

Risks

• The reduction in ownership by a significant group of reporting persons could signal a decrease in their confidence or strategic interest in Aurinia Pharmaceuticals Inc.

Future Outlook

Following the filing of this Amendment No. 17, the Reporting Persons will no longer be required to file reports under Section 13(d) of the Act with respect to the Common Shares.

Industry Context

StockSavvy.ai notes that significant reductions in beneficial ownership by large shareholders, especially those who have been filing Schedule 13Ds for an extended period, can sometimes precede a more substantial divestment or signal a shift in strategic alignment with the company's direction. This is particularly relevant in the biopharmaceutical sector where long-term investment horizons are common.

Stakeholder Impact

• Shareholders may interpret the reduction in ownership by these reporting persons as a negative signal, potentially impacting market sentiment and share price.

Next Steps

• The reporting persons will cease to be required to file reports under Section 13(d) of the Act.

Key Dates

Recommendation

While the reduction in stake by a significant holder is a negative signal, the filing itself does not provide enough information about Aurinia Pharmaceuticals' current performance or future prospects to warrant a sell recommendation. The market may react negatively in the short term, but a hold position allows for further observation of the company's performance and the reasons behind the divestment.

Keywords

Aurinia Pharmaceuticals, Schedule 13D, Beneficial Ownership, Shareholder, Securities Trading, ILJIN SNT, ILJIN Steel, Ownership Threshold